Seven Fleet Capital Management LP Buys Shares of 35,286 Denali Therapeutics Inc. $DNLI

Seven Fleet Capital Management LP purchased a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the first quarter, according to its most recent filing with the SEC. The firm purchased 35,286 shares of the company’s stock, valued at approximately $677,000.

Several other institutional investors have also modified their holdings of the company. Norges Bank acquired a new stake in shares of Denali Therapeutics in the 4th quarter worth approximately $84,525,000. ADAR1 Capital Management LLC raised its holdings in Denali Therapeutics by 3,490.9% during the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock worth $35,932,000 after purchasing an additional 1,819,339 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Denali Therapeutics by 77.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock worth $63,329,000 after purchasing an additional 1,672,098 shares during the last quarter. Temasek Holdings Private Ltd boosted its position in Denali Therapeutics by 30.9% during the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after purchasing an additional 1,657,142 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its position in Denali Therapeutics by 28.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock worth $119,766,000 after purchasing an additional 1,615,565 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Denali Therapeutics in a report on Monday, May 11th. Sanford C. Bernstein reaffirmed a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Friday, July 17th. Leerink Partners lowered their price objective on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $35.17.

Denali Therapeutics Price Performance

DNLI opened at $23.02 on Friday. The company’s 50 day simple moving average is $23.12 and its 200 day simple moving average is $21.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.28 and a current ratio of 9.28. Denali Therapeutics Inc. has a 1 year low of $12.58 and a 1 year high of $27.30. The stock has a market capitalization of $3.65 billion, a PE ratio of -7.99 and a beta of 0.96.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter in the previous year, the company earned ($0.78) earnings per share. As a group, sell-side analysts expect that Denali Therapeutics Inc. will post -2.73 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.